Table 2.
Summary of patient follow up.
| Variable | Frequency (percentage) | |
|---|---|---|
| Follow up period (years) | Median 1.8 (0.08–12.25) | |
| BCVA (eyes) | Improved | 26/87 (30%)a |
| Stable | 24/87 (28%)a | |
| Decreased | 37/87 (43%)a | |
| Duration between the first and last VF test (years) | Median 2.4 (0.7–6.8) | |
| Visual field change (eyes) | Improved | 17/59 (29%)b |
| Stable | 9/59 (15%)b | |
| Reduced | 33/59 (56%)b | |
| Not evaluated | 28/87 (32%)a | |
| Duration between the first and last OCT (years) | Median 2 (0.5–10) | |
| OCT | Stable | 21/33 (64%) |
| Worsen | 11/33 (33%) | |
| N/A | 11/44 (24%) | |
| Immunohistochemistry | Positive | 18/22 (82%) |
| Negative | 4/22 (18%) | |
| N/A | 22/44 (50%) | |
| Number of antiretinal antibodies |
Mean ± SD 4 ± 2 Range 1–11 |
|
| Duration from onset to treatment (years) | Median 7 (0.25–30) | |
| Treatment | Prednisolone | 30/44 (68%) |
| Azathioprine | 14/44 (32%) | |
| Methotrexate | 8/44 (18%) | |
| Mycophenolate | 7/44 (16%) | |
| Others c | 3/44 (7%) | |
| No treatment | 12/44 (27%) |
BCVA best corrected visual acuity, OCT optical coherence tomography, VF visual field, N/A not applicable.
aOne patient had a prosthetic eye.
bVF was compared to the baseline.
cCyclosporine, leflunamide, dexamethasone, intravenous immunoglobulins (IVIG), rituximab.